{"id":6308,"date":"2023-10-18T16:03:31","date_gmt":"2023-10-18T14:03:31","guid":{"rendered":"https:\/\/neopharm.bg\/projects\/"},"modified":"2025-08-21T08:05:49","modified_gmt":"2025-08-21T06:05:49","slug":"projects","status":"publish","type":"page","link":"https:\/\/neopharm.bg\/en\/projects\/","title":{"rendered":"<img src=\"https:\/\/neopharm.bg\/wp-content\/uploads\/2025\/08\/european-union-circle-flag-icon-vector-illustration.png\"     alt=\"EU flag\"width=\"22\" height=\"22\" style=\"vertical-align: -6px\" >Projects"},"content":{"rendered":"<div class=\"wpbf-grid wpbf-grid-small wpbf-padding-medium\">\n<div class=\"wpbf-1-2 wpbf-padding-small\">\n<img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" alt=\"Eu Logo Fund\" width=\"310\" height=\"100\" class=\"aligncenter size-full wp-image-4166 lazyload\" data-src=\"https:\/\/neopharm.bg\/wp-content\/uploads\/2025\/03\/EU1.jpg\">\n<\/div>\n<div class=\"wpbf-1-2 wpbf-padding-small\">\n<img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" alt=\"Opik Logo\" width=\"310\" height=\"80\" class=\"aligncenter size-full wp-image-4165 lazyload\" data-src=\"https:\/\/neopharm.bg\/wp-content\/uploads\/2025\/03\/EU2.png\">\n<\/div>\n<\/div>\n<div class=\"wpbf-padding-medium\">\n<strong>Project:<\/strong> BG16RFPR001-1.003-0224-C01, procedure \u201cImplementation of Innovations in Enterprises\u201d<br \/>\n<strong>Main Objective:<\/strong> Introduction into production of an innovative product for the prevention and treatment of constipation<br \/>\n<strong>Beneficiary:<\/strong> Neopharm Bulgaria Ltd.<br \/>\n<strong>Total Value:<\/strong> BGN 1,777,777, of which BGN 799,999.65 is EU funding<br \/>\n<strong>Contract Duration:<\/strong> 15 months (ending on 16.03.2026)  <\/p>\n<p>For more information, click <a href=\"https:\/\/neopharm.bg\/en\/eu-project\/\" rel=\"noopener\" target=\"_blank\"><strong>HERE<\/strong><\/a>\n<\/div>\n<div class=\"wpbf-grid wpbf-grid-small wpbf-padding-medium\">\n<div class=\"wpbf-1-2 wpbf-padding-small\">\n<img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" alt=\"Eu Logo Fund\" width=\"310\" height=\"100\" class=\"aligncenter size-full wp-image-4166 lazyload\" sizes=\"auto, (max-width: 310px) 100vw, 310px\" data-src=\"https:\/\/neopharm.bg\/wp-content\/uploads\/2023\/10\/eu_logo_fund.png\" data-srcset=\"https:\/\/neopharm.bg\/wp-content\/uploads\/2023\/10\/eu_logo_fund.png 620w, https:\/\/neopharm.bg\/wp-content\/uploads\/2023\/10\/eu_logo_fund-300x97.png 300w\">\n<\/div>\n<div class=\"wpbf-1-2 wpbf-padding-small\">\n<img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" alt=\"Opik Logo\" width=\"310\" height=\"100\" class=\"aligncenter size-full wp-image-4165 lazyload\" sizes=\"auto, (max-width: 310px) 100vw, 310px\" data-src=\"https:\/\/neopharm.bg\/wp-content\/uploads\/2023\/10\/opik_logo.png\" data-srcset=\"https:\/\/neopharm.bg\/wp-content\/uploads\/2023\/10\/opik_logo.png 620w, https:\/\/neopharm.bg\/wp-content\/uploads\/2023\/10\/opik_logo-300x97.png 300w\">\n<\/div>\n<\/div>\n<div class=\"wpbf-padding-medium\">\n<strong>Project:<\/strong> BG16RFOP002-1.005-0150, \u201cInnovation and Development at Neopharm Bulgaria Ltd.\u201d<br \/>\n<strong>Main Objective:<\/strong> Promotion of innovation and research activities at Neopharm Bulgaria Ltd.<br \/>\n<strong>Beneficiary:<\/strong> Neopharm Bulgaria Ltd.<br \/>\n<strong>Partner:<\/strong> Institute of Microbiology \u201cStefan Angelov\u201d \u2013 Bulgarian Academy of Sciences<br \/>\n<strong>Total Value:<\/strong> BGN 436,038.00, of which BGN 320,514.70 is a grant, as follows: BGN 272,437.50 EU co-financing and BGN 48,077.20 national co-financing<br \/>\n<strong>Start:<\/strong> 16.11.2018<br \/>\n<strong>End:<\/strong> 16.11.2020\n<\/div>\n<div class=\"wpbf-grid wpbf-grid-small wpbf-padding-medium\">\n<div class=\"wpbf-1-2 wpbf-padding-small\">\n<img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" alt=\"Eu Logo Fund\" width=\"310\" height=\"100\" class=\"aligncenter size-full wp-image-4166 lazyload\" sizes=\"auto, (max-width: 310px) 100vw, 310px\" data-src=\"https:\/\/neopharm.bg\/wp-content\/uploads\/2023\/10\/eu_logo_fund.png\" data-srcset=\"https:\/\/neopharm.bg\/wp-content\/uploads\/2023\/10\/eu_logo_fund.png 620w, https:\/\/neopharm.bg\/wp-content\/uploads\/2023\/10\/eu_logo_fund-300x97.png 300w\">\n<\/div>\n<div class=\"wpbf-1-2 wpbf-padding-small\">\n<img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" alt=\"Opik Logo\" width=\"310\" height=\"100\" class=\"aligncenter size-full wp-image-4165 lazyload\" sizes=\"auto, (max-width: 310px) 100vw, 310px\" data-src=\"https:\/\/neopharm.bg\/wp-content\/uploads\/2023\/10\/opik_logo.png\" data-srcset=\"https:\/\/neopharm.bg\/wp-content\/uploads\/2023\/10\/opik_logo.png 620w, https:\/\/neopharm.bg\/wp-content\/uploads\/2023\/10\/opik_logo-300x97.png 300w\">\n<\/div>\n<\/div>\n<div class=\"wpbf-padding-medium\">\n<strong>Project:<\/strong> BG16RFOP002-2.077-0600<br \/>\n<strong>Main Objective:<\/strong> Support for medium-sized enterprises to overcome the economic consequences of the COVID-19 pandemic, ensuring working capital for Bulgarian medium-sized enterprises to cope with the impact of the COVID-19 crisis.<br \/>\n<strong>Beneficiary:<\/strong> Neopharm Bulgaria Ltd.<br \/>\n<strong>Total Value:<\/strong> BGN 150,000.00, of which BGN 127,500.00 EU co-financing and BGN 22,500.00 national co-financing<br \/>\n<strong>Start:<\/strong> 01.02.2021<br \/>\n<strong>End:<\/strong> 01.05.2021\n<\/div>\n<div class=\"wpbf-grid wpbf-grid-small wpbf-padding-medium\">\n<div class=\"wpbf-1-2 wpbf-padding-small\">\n<img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" alt=\"Eu Logo Fund\" width=\"310\" height=\"100\" class=\"aligncenter size-full wp-image-4166 lazyload\" sizes=\"auto, (max-width: 310px) 100vw, 310px\" data-src=\"https:\/\/neopharm.bg\/wp-content\/uploads\/2023\/10\/eu_logo_fund.png\" data-srcset=\"https:\/\/neopharm.bg\/wp-content\/uploads\/2023\/10\/eu_logo_fund.png 620w, https:\/\/neopharm.bg\/wp-content\/uploads\/2023\/10\/eu_logo_fund-300x97.png 300w\">\n<\/div>\n<div class=\"wpbf-1-2 wpbf-padding-small\">\n<img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" alt=\"Opik Logo\" width=\"310\" height=\"100\" class=\"aligncenter size-full wp-image-4165 lazyload\" sizes=\"auto, (max-width: 310px) 100vw, 310px\" data-src=\"https:\/\/neopharm.bg\/wp-content\/uploads\/2023\/10\/opik_logo.png\" data-srcset=\"https:\/\/neopharm.bg\/wp-content\/uploads\/2023\/10\/opik_logo.png 620w, https:\/\/neopharm.bg\/wp-content\/uploads\/2023\/10\/opik_logo-300x97.png 300w\">\n<\/div>\n<\/div>\n<div class=\"wpbf-padding-medium\">\n<strong>Project:<\/strong> Recovery of SMEs through Improving Energy Efficiency<br \/>\n<strong>Procedure:<\/strong> BG16RFOP002-6.002<br \/>\n<strong>Beneficiary:<\/strong> Neopharm Bulgaria Ltd.<br \/>\n<strong>Start:<\/strong> 16.09.2022<br \/>\n<strong>End:<\/strong> 16.03.2023<br \/>\n<strong>Total Value:<\/strong> BGN 287,500.00<br \/>\n<strong>Grant:<\/strong> BGN 143,750.00, representing 100% financing from the European Regional Development Fund under REACT-EU<br \/>\n<strong>Main Objective:<\/strong> Improving the company\u2019s energy efficiency through the installation of new climate chambers\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Project: BG16RFPR001-1.003-0224-C01, procedure \u201cImplementation of Innovations in Enterprises\u201d Main Objective: Introduction into production of an innovative product for the prevention and treatment of constipation Beneficiary: Neopharm Bulgaria Ltd. Total Value: BGN 1,777,777, of which BGN 799,999.65 is EU funding Contract Duration: 15 months (ending on 16.03.2026) For more information, click HERE Project: BG16RFOP002-1.005-0150, \u201cInnovation and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":5,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"slim_seo":{"title":"Projects - Neopharm","description":"Project: BG16RFPR001-1.003-0224-C01, procedure \u201cImplementation of Innovations in Enterprises\u201d Main Objective: Introduction into production of an innovative prod"},"footnotes":""},"class_list":["post-6308","page","type-page","status-publish","hentry","wpbf-post"],"acf":[],"_links":{"self":[{"href":"https:\/\/neopharm.bg\/en\/wp-json\/wp\/v2\/pages\/6308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neopharm.bg\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/neopharm.bg\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/neopharm.bg\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/neopharm.bg\/en\/wp-json\/wp\/v2\/comments?post=6308"}],"version-history":[{"count":2,"href":"https:\/\/neopharm.bg\/en\/wp-json\/wp\/v2\/pages\/6308\/revisions"}],"predecessor-version":[{"id":7676,"href":"https:\/\/neopharm.bg\/en\/wp-json\/wp\/v2\/pages\/6308\/revisions\/7676"}],"wp:attachment":[{"href":"https:\/\/neopharm.bg\/en\/wp-json\/wp\/v2\/media?parent=6308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}